Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune

A Novel Targeted Oncology Platform

 
• By Andrew McConaghie

Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.

Seattle
Morphimmune will now relocate its headquarters to Seattle, its new CEO's home territory. • Source: Shutterstock

More from Leadership

More from Scrip